bioAffinity Technologies, Inc. (BIAF) Insider Trading Activity

NASDAQ$15.27
Market Cap
$6.4M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
458 of 853
Rank in Industry
16 of 39

BIAF Insider Trading Activity

BIAF Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About bioAffinity Technologies, Inc.

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Insider Activity of bioAffinity Technologies, Inc.

Over the last 12 months, insiders at bioAffinity Technologies, Inc. have bought $0 and sold $0 worth of bioAffinity Technologies, Inc. stock.

On average, over the past 5 years, insiders at bioAffinity Technologies, Inc. have bought $99,997 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,448 shares for transaction amount of $0 was made by Edwards James Michael (Chief Financial Officer) on 2022‑09‑01.

List of Insider Buy and Sell Transactions, bioAffinity Technologies, Inc.

2022-09-01PurchaseEdwards James MichaelChief Financial Officer
2,448
$0
$0
-77.35%
2022-08-31PurchaseRubin Gary Ddirector
32,652
0.5281%
$3.06
$99,997
-77.35%
2022-08-31PurchaseGIRGENTI STEVENExecutive Chairman
40,916
$0
$0
-77.35%
2022-08-31PurchaseKNIGHT PETER Sdirector
8,163
$0
$0
-77.35%
2022-08-31PurchaseZannes MariaPresident, CEO
16,326
$0
$0
-77.35%
Total: 5

Insider Historical Profitability

<0.0001%
Rubin Gary Ddirector
1584144
378.1938%
$24.19M10
<0.0001%
GIRGENTI STEVENExecutive Chairman
861099
205.5762%
$13.15M10
Edwards James MichaelChief Financial Officer
30323
7.2392%
$463,032.2110
KNIGHT PETER Sdirector
22448
5.3592%
$342,780.9610
Zannes MariaPresident, CEO
19897
4.7501%
$303,827.1910

Historical Insider Profitability vs. Competitors

$12,747,816
646
-0.37%
$39.25M
$77,713,850
205
10.50%
$268.35M
$26,663,659
7
-12.13%
$47B
$66,999
2
-47.60%
$1.44M
bioAffinity Technologies, Inc.
(BIAF)
$99,997
1
-77.35%
$6.4M

BIAF Institutional Investors: Active Positions

Increased Positions7+36.84%75,222+24.79%
Decreased Positions9-47.37%298,408-98.35%
New Positions4New65,903New
Sold Out Positions7Sold Out271,762Sold Out
Total Postitions17-10.53%80,213-73.56%

BIAF Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Sabby Management, Llc$296.006.07%242,757+242,757New2025-09-30
Ifp Advisors, Inc$32.000.65%25,833+25,000+3,001.2%2025-09-30
Scientech Research Llc$20.000.42%16,583+16,583New2025-09-30
Vanguard Group Inc$13.000.26%10,429+9,074+669.67%2025-09-30
Tower Research Capital Llc (Trc)$3.000.06%2,499+2,395+2,302.89%2025-09-30
Allworth Financial Lp$2.000.05%1,79100%2025-09-30
Sheaff Brock Investment Advisors, Llc$2.000.05%1,791+248+16.07%2025-03-31
Bank Of America Corp /De/$2.000.04%1,684+1,677+23,957.14%2025-09-30
Ubs Group Ag$0<0.01%143+142+14,200%2025-09-30
Citigroup Inc$0<0.01%75+26+53.06%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.